
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Utilizing our senses-sight, hearing, AND smell-during the patient interview can provide a comprehensive exam and assist in assessment and treatment.
